AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05343221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Fidelity Simulator
Description: First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the High Fidelity CPR Simulator. This simulator is adult human sized and specialized for CPR practice. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
Study NCT05343221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haptic
Description: First of all, students will be given 1 hour of CPR training. Then they will be asked to apply with the 3D technology Haptic Device Simulator. This tool has a computer screen and a swing haptic pen. It will not be interfered during the application. The student's practice will be evaluated by an observer. The student will evaluate his/her satisfaction after the application is over.
Study NCT04726189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercises
Description: Consists of a a standard exercise program with range of motion exercises from the third week and elastic band exercise from the sixth week.
Study NCT04726189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard exercises plus Early progressive exercises
Description: This exercise program consists of standard exercises plus the early progressive program that initiates early (second week) and continues with resistance exercises with progression of the load according to individual participant toleration. Exercises are isometric exercises from the second week and then gradually progression of load in seated heel-rise and resistance band exercises.
Study NCT06126861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]LP-168
Description: single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state
Study NCT05652322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Pill 150% equivalent iv dose
Description: change from intravenous to oral furosemide
Study NCT05652322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Pill 200% equivalent iv dose
Description: change from intravenous to oral furosemide
Study NCT05652322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: change from intravenous to oral furosemide
Study NCT06406322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
Study NCT06406322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Pelvic floor muscle training will be given to patients with strengthening and endurance exercises for 8 weeks. PFMT will be applied at a patient-specific progression for 8 weeks.Exercises will be given in different positions (supine, sitting, etc.).
Study NCT06406322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will be applied as a progressive program in the form of a walking program, at least 4 days a week for 8 weeks. There will be 5-minute warm-up and cool-down periods (walking at a light pace) before and after exercise.
Study NCT06412926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 44-4400
Description: Film-coated tablet, oral use
Study NCT06486220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal bacteria freeze-dried powder capsules
Description: Oral healthy intestinal bacteria freeze-dried powder capsules, tid
Study NCT04415333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate 5 mmol
Description: Enema-based delivery of 5 mmol butyrate in 0.9% saline, (60 mL total)
Study NCT04415333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Butyrate 80 mmol
Description: Enema-based delivery of 80 mmol butyrate in 0.9% saline, (60 mL total)
Study NCT06264648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure sensitivity education
Description: Therapists were asked to apply pressure to the scale with estimated weights of 0.5 kg, 1 kg, 2 kg and 4 kg. In each measurement, the value shown on the scale was recorded without being shown to the participant.After the measurements, the participants were made to experiment when the digital screen can be seen, in order to teach the physiotherapists how much pressure they applied to reach the target weight. Participants were given a total of 10 minutes for the trials. Then, the digital screen was hidden again, and the therapist was asked to apply 0.5 kg, 1 kg, 2 kg and 4 kg weight in a randomized order and maintain this pressure for 5 seconds. The weight fixed by the therapist for 5 seconds was noted by the researcher; the participant was not informed about the values on the digital screen.
Study NCT04910919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: Participants 51 - 100 will receive the standard of care treatment as usual plus 1 tsp of honey with every dose of acetaminophen.
Study NCT04910919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
Study NCT04910919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The first 50 participants will receive treatment as usual (alternating weight-based dosing of acetaminophen and ibuprofen with a PRN three-day supply of opioid analgesic).
Study NCT04610034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Caregivers
Description: Resilient Caregivers is a 7-session group program developed for partner caregivers of patients with cancer (6 weekly sessions and 1 booster session). Each session takes place in groups of approximately 8 participants and lasts for two-and-a-half hours. Sessions 1 to 3 focuses on the caregiver and introduces the resilience components of coping strategies, meta-reflective skill and clarification of values. Sessions 4 and 5 focuses on these components in the relationship between the caregiver and the cancer patient and social support networks respectively, while Session 6 focuses on resilience in relation to self-care and care for the partner. A booster session will be scheduled one month after the end of Session 6 in order to follow-up on the intervention and allow participants to reflect on the benefits and challenges of the program.
Study NCT04610034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: The control arm will receive usual care, which implies no systematic support.
Study NCT05220228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 1mg prucalopride x 2d, 2mg prucalopride x 5-8d
Study NCT05220228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose / sucrose placebo
Study NCT06064708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: The experimental group received 30 minutes of MBI according to Smith's (2005) MBI protocol, which is a standardized theory-based intervention.~Smith's (2005) MBI protocol comprises six components:~1. Being mindful of the breath (5 minutes).~2. Being mindful of the body (5 minutes).~3. Being mindful of the thought (5 minutes)~4. Being mindful of the sound (5 minutes)~5. Being mindful during walking (5 minutes)~6. Full meditation (5 minutes).
Study NCT04606069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson will be given intravenously as 5 ug/kg (up to 400 mg/patient) loading dose over 30 mins (to avoid unpleasant side effects sometimes associated with the rapid bolus injection of Regadenoson), followed by a continuous slow infusion (1.44micrograms/kg/hour) with the use of a pediatric infusion pump for 6 hours.
Study NCT04606069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: The same volume of saline will be given intravenously for 6 and half hours.
Study NCT05359913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical cancer podcast for African American women
Description: The video podcast will deliver cervical cancer prevention messages using entertainment education and behavioral journalism, and film production techniques such as talking head video, interview, animations, \& live-action skits. The research team will work closely with the production company in scripting the video vignettes and sequences, ensuring that video content reflects salient domains captured in the concept mapping research development phase of the study.
Study NCT05829096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The COMBINED approach
Description: 1. Patient-level intervention:~   * Assessment of existing lifestyle factors (smoking status, physical activity levels, and weight) that may be relevant to shoulder pain;~  * Brief intervention to support health behaviour change: smoking cessation, increasing physical activity levels and consuming a healthy diet~  * Supporting tools for behaviour change, including an activity workbook for goal-setting and a diary for self-monitoring.~2. Clinician-level implementation toolkit:~   * Training package including a face-to-face workshop, training manual, recorded role play simulations and an online follow-up training session~  * Additional supporting resources; a step-by-step guide to The COMBINED approach, scripts, patient signposting information to support services and a lay summary infographic to explain the links between the health behaviours and RC disorders to patients~  * Audit and feedback via observations of consultations to address any 'drift' from the intervention delivery as intended
Study NCT05271084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram (tablet) 20 mg + Pentoxifylline (tablet) 400Mg
Description: Selective serotonin reuptake inhibitor (SSRI) + phosphodiesterase inhibitor with anti-inflammatory properties
Study NCT05271084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram (tablet) 20 mg + Placebo (tablet)
Description: Selective serotonin reuptake inhibitor (SSRI) + placebo
Study NCT05271019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold load device
Description: Inspiratory Muscle Training (IMT) for 3 months:~Though a threshold loading device (5 sets of 6 repetitions, 1session/day, 5 days/week). the inspiratory load will start at 30% of MIP, or up to the maximum patient-tolerable load (max 60% of MIP), no more than 3-5/10 on the modified Borg scale.
Study NCT06317233 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pelvic Pain Treatment Guide
Description: The treatment guide includes mobile and web-based resources and applications specifically chosen to empower patients with information and to promote self-efficacy. The treatment guide is designed to be easily understood, visually appealing, and largely translatable from institution to institution. Patients using the treatment guide will be followed with a clearly defined follow up schedule, which includes touch points between appointments to aid with resource navigation.
Study NCT05728086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group art therapy
Description: The intervention is a manualised programme of group art therapy based on a bio-psychosocial therapeutic model. The programme is made up of six 60 - 90-minute art therapy group sessions facilitated by an experienced HCPC (Health and Care Professions Council) registered Art Therapists trained in the intervention.
Study NCT05142514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine HIPRA
Description: Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
Study NCT05142514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cominarty (Pfizer-BioNtech)
Description: Subjects will receive 2 injections of Cominarty administered 21 days apart
Study NCT04767256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and dexmedetomidine
Description: General anesthesia was induced with sufentanil 0.5-0.8 ug/kg, propofol 1.5-2.0 mg/kg, and rocuronium 0.5-1.0 mg/kg. Intravenous dexamethasone 10 mg was injected and a 50-ml syringe containing dexmedetomidine 1 ug/kg in 0.9% saline was infused after induction of general anaesthesia over a 30-min period. Anesthesia was maintained by remifentanil and sevoflurane to keep the Narcotrend index reading between 40 and 60.
Study NCT04767256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine 1 ug/kg was infused after induction of general anaesthesia over a 30-min period.
Study NCT04767256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided lumbar erector spinae plane block
Description: The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
Study NCT04767256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar erector spinae plane block
Description: The probe was installed in the sagittal axis in the midline at the L3 vertebral level. The spinous processes were ﬁrst visualized, after which the probe was lateralized, and the transverse processes and the erector spinae muscle were visualized approximately 3 cm laterally to the midline. The needle was advanced between the transverse process and the deep fascia of the erector spinae muscle from the caudal to the cranial using in-plane technique. The location of the needle was confirmed with 2mL saline solution, after which 20 mL of 0.4% ropivacaine was administered.
Study NCT04767256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PCIA
Description: Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
Study NCT04767256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCIA
Description: Intravenous PCA included 0.9% saline with sufentanil and was programmed to run at 2ml with a 1-ml bolus dose and a 10-min lockout time. The patients with VAS more than 4 despite using intravenous PCA were treated with rescue analgesics comprising intravenous parecoxib.
Study NCT05078463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Maltose Microneedle Patch (Patch Size: 1 cm x 1 cm, 36 microneedles per patch, microneedle's height, base width and tip radius are 400 μm, 100 μm and 3 μm, respectively) will be firmly applied for 5 seconds on the 1 cm x 1 cm site for IV cannulation on the dorsal surface of the hand for blood transfusion, prior to EMLA cream application.
Study NCT05078463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)
Description: 1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
Study NCT05078463 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1 Finger Tip Unit (FTU) EMLA Cream (30-minute application time)
Description: 1 Finger Tip Units (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
Study NCT05078463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 Finger Tip Unit (FTU) EMLA (15-minute application time)
Description: 1 Finger Tip Unit (FTU) EMLA applied for 15 minutes on the dorsal surface of the IV cannulated hand
Study NCT05078463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)
Description: 0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
Study NCT05078463 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Patch
Description: A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of a size of 1cm x 1cm will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid on the dorsal surface of the IV cannulated hand for blood transfusion.
Study NCT05191823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
Description: 200 mg DHA+ 200 mg AA per day for 6 months
Study NCT05191823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg corn oil per day for 6 months
Study NCT05903534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Endurance and Limb Strengthening Program (PEDALS) and Lower Limb Strength Training
Description: Pediatric Endurance and Limb Strengthening Program (PEDALS) Group This will receive stationary cycling
Study NCT05903534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Limb Strength Training Group
Description: Lower Limb Strength Training Group
Study NCT05957627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saleem's protocol
Description: It involved 2 principal tenotmies and 2 accessory tenotmies. Principal tenotmies include tendo achillies and planter fascia release. 2 Accessory tenotmies include tibialis posterior and abductor hallucis. All tenotmies are done under local anesthesia
Study NCT05136443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate 0.25% ophthalmic suspension
Description: tapering dose
Study NCT05675956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group with 100% intensity setting on Apollo Neuro device
Description: The group will have the device set to 100% intensity at one of their two experimental visits.
Study NCT05675956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator group with 10% intensity setting on the Apollo Neuro device
Description: The group will have the device set to 10% intensity at one of their two experimental visits.
Study NCT06084117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNO
Description: Respiratory support with HFNO (as opposed to NIV, as per standard of care)
Study NCT06084117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIV
Description: Respiratory support with Non-invasive ventilation, standard of care
Study NCT05468944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal specimen extraction robotic surgery
Description: Participants in this group underwent robotic rectal cancer resection ,the specimens were extracted through anus.
Study NCT05861050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05861050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05861050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04847882 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire submitted to the parents of children with cystic fibrosis aged 6 to 17 years and to controls in order to assess and compare the prevalence of sleep disorders and their main non-respiratory causes
Study NCT04899687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
Study NCT05468944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal specimen extraction robotic surgery
Description: Participants in this group underwent robotic assisted rectal cancer resection ,the specimens were extracted through the incision on the abdominal wall.
Study NCT05457933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg, every day before breakfast. Glargine insulin 300 Units/mL, average dose: 10-20 U/day; Insulin lispro 100 Units/mL, average dose: 10-30 U/day
Study NCT05457933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine insulin; 300 Units/mL, average dose: 10-20 U/day, Insulin lispro 100 Units/mL, average dose: 10-30 U/day
Study NCT05199350 — intervention group
Intervention type: OTHER
Intervention: Device Name: ANSiscope
Description: Heart rate variability measurement and vital signs monitoring will be performed on all subjects.
Study NCT06530602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 D SPA (shoulder complex pain alignment) Moblization
Description: 3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
Study NCT06530602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Moblization (KaltenBorn)
Description: 3 per week, mobilization for 5 mins and 30 min session for total 3 weeks , exercises 3 sets for 10 repetitions.
Study NCT05861050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05861050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV
Study NCT05861050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO